ASX:ATX Amplia Therapeutics (ATX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Amplia Therapeutics Stock (ASX:ATX) 30 days 90 days 365 days Advanced Chart Get Amplia Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume77,249 shsAverage VolumeN/AMarket CapitalizationA$30.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors.It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Read More Receive ATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATX Stock News HeadlinesAmplia Therapeutics Announces Change in Substantial Holder InterestsJune 19, 2025 | msn.comHealth Check: A pancreatic cancer ‘cure’ has been elusive, but Amplia may have cracked the nutJune 17, 2025 | msn.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 5 at 2:00 AM | Porter & Company (Ad)PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIALJune 16, 2025 | gurufocus.comMonday's HotCopper trends: 4DS falls short, $30B bid for Santos | June 16, 2025June 16, 2025 | msn.comFavourable Signals For Amplia Therapeutics: Numerous Insiders Acquired StockJune 2, 2025 | finance.yahoo.comAmplia Therapeutics Releases 2025 Corporate Governance StatementMay 30, 2025 | tipranks.comDr Boreham’s Crucible: This pancreatic cancer tackler has faith its ‘good science will prevail’May 26, 2025 | msn.comSee More Headlines ATX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Amplia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplia Therapeutics investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU), VelocityShares 1x Long VSTOXX Futures ETN (EVIX) and First Trust United Kingdom AlphaDEX Fund (FKU). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:ATX CIKN/A Webwww.ampliatx.com Phone61 2 8003 3650FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$4.50 million Net Margins-101.14% Pretax MarginN/A Return on Equity-34.42% Return on Assets-17.04% Debt Debt-to-Equity Ratio13.89 Current Ratio1.98 Quick Ratio5.05 Sales & Book Value Annual SalesA$4.45 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.88 Book ValueA$0.06 per share Price / BookN/AMiscellaneous Outstanding Shares274,800,000Free FloatN/AMarket CapA$30.65 million OptionableNot Optionable Beta0.72 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (ASX:ATX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
